A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

Systemic atopic dermatitis treatments that have acceptable safety are needed.To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic dermatitis.In this phase 3, double-blind study (Rising Up), Japanese pati...

Spremljeno u:

Bibliografski detalji
Glavni autori:	Norito Katoh, Yukihiro Ohya, Hiroyuki Murota, Masanori Ikeda, Xiaofei Hu, Kimitoshi Ikeda, John Liu, Takuya Sasaki, Alvina D. Chu, Henrique D. Teixeira, Hidehisa Saeki
Format:	Artigo
Jezik:	engleski
Izdano:	2021
Online pristup:	https://doi.org/10.1016/j.jdin.2021.11.001 http://www.jaadinternational.org/article/S2666328721000894/pdf
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis
od: Katoh, Norito, i dr.
Izdano: (2021)

Japanese guidelines for atopic dermatitis 2020
od: Norito Katoh, i dr.
Izdano: (2020)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
od: Teppei Hagino, i dr.
Izdano: (2023)

Clinical practice guidelines for the management of atopic dermatitis 2018
od: Norito Katoh, i dr.
Izdano: (2019)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
od: Teppei Hagino, i dr.
Izdano: (2024)

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
od: Eric L. Simpson, i dr.
Izdano: (2022)

The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis
od: Teppei Hagino, i dr.
Izdano: (2023)

The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis
od: Teppei Hagino, i dr.
Izdano: (2023)

Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks
od: Teppei Hagino, i dr.
Izdano: (2024)

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
od: Teppei Hagino, i dr.
Izdano: (2024)

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
od: Jonathan I. Silverberg, i dr.
Izdano: (2021)

Japanese guidelines for atopic dermatitis 2017
od: Ichiro Katayama, i dr.
Izdano: (2017)

Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with <scp>moderate‐to‐severe</scp> atopic dermatitis
od: Teppei Hagino, i dr.
Izdano: (2023)

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
od: Teppei Hagino, i dr.
Izdano: (2024)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
od: Andrew Blauvelt, i dr.
Izdano: (2021)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
od: Katoh, Norito, i dr.
Izdano: (2019)

Effect of upadacitinib on atopic hand eczema in patients with moderate‐to‐severe atopic dermatitis: Results from two randomized phase 3 trials
od: Eric L. Simpson, i dr.
Izdano: (2023)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
od: Teppei Hagino, i dr.
Izdano: (2023)

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis
od: Amy S. Paller, i dr.
Izdano: (2023)

Treatment of atopic dermatitis with upadacitinib: adcare single center experience
od: Daria Fomina, i dr.
Izdano: (2024)

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
od: Emma Guttman‐Yassky, i dr.
Izdano: (2022)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
od: Blauvelt, Andrew, i dr.
Izdano: (2021)

The Roles of Sex Hormones in the Course of Atopic Dermatitis
od: Kanda, Naoko, i dr.
Izdano: (2019)

The Roles of Sex Hormones in the Course of Atopic Dermatitis
od: Naoko Kanda, i dr.
Izdano: (2019)

Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
od: Andrea Chiricozzi, i dr.
Izdano: (2023)

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
od: Luigi Gargiulo, i dr.
Izdano: (2023)

Atopic Dermatitis: Identification and Management of Complicating Factors
od: Tamagawa-Mineoka, Risa, i dr.
Izdano: (2020)

Atopic Dermatitis: Identification and Management of Complicating Factors
od: Risa Tamagawa‐Mineoka, i dr.
Izdano: (2020)

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials
od: Simpson, Eric L., i dr.
Izdano: (2022)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
od: Nogueira, Miguel, i dr.
Izdano: (2021)

Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults
od: Axel De Greef, i dr.
Izdano: (2023)

Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report
od: Ting Pan, i dr.
Izdano: (2023)

Guidelines for management of atopic dermatitis
od: Hidehisa Saeki, i dr.
Izdano: (2009)

Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report
od: Cantelli, Mariateresa, i dr.
Izdano: (2022)

Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report
od: Mariateresa Cantelli, i dr.
Izdano: (2022)

Japanese Guideline for Atopic Dermatitis 2014
od: Ichiro Katayama, i dr.
Izdano: (2014)

Exacerbating factors of itch in atopic dermatitis
od: Hiroyuki Murota, i dr.
Izdano: (2016)

Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)
od: Jonathan I. Silverberg, i dr.
Izdano: (2025)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
od: Nezamololama, Novin, i dr.
Izdano: (2020)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
od: Novin Nezamololama, i dr.
Izdano: (2020)